Back

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

2 September 2024 (12:45 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy Hypertrophic Cardiomyopathy Open Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Maria Rita Lima

Hospital Santa Cruz, Lisbon (Portugal)

3 More presentations in this session

Presentation thumbnail
Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy
Doctor A. Milazzo (Florence, IT)
Abstract Slides Video
Presentation thumbnail
A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.
Doctor A. Elmorsy (Tanta, EG)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 12:45 CET
You may be interested in
thumbnail
Congress Presentation
Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
thumbnail
Congress Session
Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
thumbnail
Congress Session
Hypertrophic cardiomyopathy (HCM) summit: navigating patient cases

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources